Roche continued its strong momentum and upgraded 2019 guidance for the second time. While the Q2 sales growth of 9% at CER was largely driven by Pharmaceuticals (+11%), Diagnostics’ (+4%) reflected a recovery from the one-off setbacks of Q1. The new drugs continued to hold up well, more than compensating for the erosion of the legacy drugs. As the company moves deeper into the biosimilar battle, it is this balance, which would be critical.
30 Jul 2019
Another quarter, another upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another quarter, another upgrade
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
30 Jul 2019 -
Author:
Kamla Singh -
Pages:
4
Roche continued its strong momentum and upgraded 2019 guidance for the second time. While the Q2 sales growth of 9% at CER was largely driven by Pharmaceuticals (+11%), Diagnostics’ (+4%) reflected a recovery from the one-off setbacks of Q1. The new drugs continued to hold up well, more than compensating for the erosion of the legacy drugs. As the company moves deeper into the biosimilar battle, it is this balance, which would be critical.